Inhibitory effect of baicalin on collagen-induced arthritis in rats through the nuclear factor-κB pathway

Journal of Pharmacology and Experimental Therapeutics

Volumn 350, Issue 2, 2014, Pages 435-443

  Wang, Hong Zhi ^a   Wang, Hai He ^a   Huang, Shi Shun ^a   Zhao, Hong ^a   Cao, Yong Gang ^a   Wang, Guang Zhi ^a   Wang, Dong ^a   Wang, Zhi Gang ^a   Liu, Yan Hong ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; METHOTREXATE; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEACETYLATION; DISEASE COURSE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; FEMALE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SYNOVIOCYTE; TREATMENT DURATION; UPREGULATION;

ACETYLATION; ANIMALS; ARTHRITIS, EXPERIMENTAL; FEMALE; FLAVONOIDS; HUMANS; INTERLEUKIN-1BETA; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SIRTUIN 1; SYNOVIAL MEMBRANE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905001540     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.215145     Document Type: Article

References (34)

1. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V, and Ciliberto G (1998) Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med 187:461-468.
2. Bartok B and Firestein GS (2010) Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233:233-255.
3. Brand DD, Kang AH, and Rosloniec EF (2003) Immunopathogenesis of collagen arthritis. Springer Semin Immunopathol 25:3-18.
4. Cai X, Zhou H, Wong YF, Xie Y, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, and Liu L (2007) Suppression of the onset and progression of collagen-induced arthritis in rats by QFGJS, a preparation from an anti-arthritic Chinese herbal formula. J Ethnopharmacol 110:39-48.
5. Cao Y, Mao X, Sun C, Zheng P, Gao J, Wang X, Min D, Sun H, Xie N, and Cai J (2011) Baicalin attenuates global cerebral ischemia/reperfusion injury in gerbils via anti-oxidative and anti-apoptotic pathways. Brain Res Bull 85:396-402.
6. Chen LF, Mu Y, and Greene WC (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 21:6539-6548.
7. Du F, Lü LJ, Fu Q, Dai M, Teng JL, Fan W, Chen SL, Ye P, Shen N, and Huang XF, et al. (2008) T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis. Arthritis Res Ther 10:1-11.
8. Feldmann M, Brennan FM, and Maini RN (1996) Rheumatoid arthritis. Cell 85: 307-310.
9. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, and Weaver AL, et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443-1450.
10. Guo M, Zhang N, Li D, Liang D, Liu Z, Li F, Fu Y, Cao Y, Deng X, and Yang Z (2013) Baicalin plays an anti-inflammatory role through reducing nuclear factor-κB and p38 phosphorylation in S. aureus-induced mastitis. Int Immunopharmacol 16: 125-130.
11. Han Z, Boyle DL, Manning AM, and Firestein GS (1998) AP-1 and NF-kappaB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28:197-208.
12. Hou J, Wang J, Zhang P, Li D, Zhang C, Zhao H, Fu J, Wang B, and Liu J (2012) Baicalin attenuates proinflammatory cytokine production in oxygen-glucose deprived challenged rat microglial cells by inhibiting TLR4 signaling pathway. Int Immunopharmacol 14:749-757.
13. Ivashkiv LB (1996) Cytokine expression and cell activation in inflammatory arthritis. Adv Immunol 63:337-376.
14. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663.
15. Kim YJ, Kim HC, Ko H, Amor EC, Lee JW, and Yang HO (2012) Inhibitory effects of aurentiacin from Syzygium samarangense on lipopolysaccharide-induced inflammatory response in mouse macrophages. Food Chem Toxicol 50:1027-1035.
16. Lanzillotta A, Sarnico I, Ingrassia R, Boroni F, Branca C, Benarese M, Faraco G, Blasi F, Chiarugi A, and Spano P, et al. (2010) The acetylation of RelA in Lys310 dictates the NF-kB-dependent response in post-ischemic injury. Cell Death Dis 1: e96.
17. Lee JH and Kim GH (2010) Evaluation of antioxidant and inhibitory activities for different subclasses flavonoids on enzymes for rheumatoid arthritis. J Food Sci 75: H212-H217.
18. Lee SJ, Nam WD, Na HJ, Cho YL, Ha KS, Hwang JY, Lee H, Kim SO, Kwon YG, and Kim YM (2008) CT20126, a novel immunosuppressant, prevents collagen-induced arthritis through the down-regulation of inflammatory gene expression by inhibiting NF-kappaB activation. Biochem Pharmacol 76:79-90.
19. Li Y, Wang S, Wang Y, Zhou C, Chen G, Shen W, Li C, Lin W, Lin S, and Huang H, et al. (2013) Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res 161:89-98.
20. Liu LL, Gong LK, Wang H, Xiao Y, Wu XF, Zhang YH, Xue X, Qi XM, and Ren J (2008) Baicalin inhibits macrophage activation by lipopolysaccharide and protects mice from endotoxin shock. Biochem Pharmacol 75:914-922.
21. Lixuan Z, Jingcheng D, Wenqin Y, Jianhua H, Baojun L, and Xiaotao F (2010) Baicalin attenuates inflammation by inhibiting NF-kappaB activation in cigarette smoke induced inflammatory models. Pulm Pharmacol Ther 23:411-419.
22. Luo X, Zuo X, Mo X, Zhou Y, and Xiao X (2011) Treatment with recombinant Hsp72 suppresses collagen-induced arthritis in mice. Inflammation 34:432-439.
23. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, and Makarov SS (1998) NF-kappaB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sci USA 95:13859-13864.
24. Odeh M (1998) Role of cytokines in rheumatoid arthritis. Drug News Perspect 11: 331-341.
25. Shou J, Bull CM, Li L, Qian HR, Wei T, Luo S, Perkins D, Solenberg PJ, Tan SL, and Chen XY, et al (2006) Identification of blood biomarkers of rheumatoid arthritis by transcript profiling of peripheral blood mononuclear cells from the rat collagen-induced arthritis model. Arthritis Res Ther 8:1-14.
26. Tak PP and Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7-11.
27. Tsao PW, Suzuki T, Totsuka R, Murata T, Takagi T, Ohmachi Y, Fujimura H, and Takata I (1997) The effect of dexamethasone on the expression of activated NF-kappa B in adjuvant arthritis. Clin Immunol Immunopathol 83:173-178.
28. Wang Z, Yao T, and Song Z (2010) Involvement and mechanism of DGAT2 upregulation in the pathogenesis of alcoholic fatty liver disease. J Lipid Res 51:3158-3165.
29. Xu XF, Cai BL, Guan SM, Li Y, Wu JZ, Wang Y, and Liu B (2011) Baicalin induces human mucoepidermoid carcinoma Mc3 cells apoptosis in vitro and in vivo. Invest New Drugs 29:637-645.
30. Yang M, Xiao C, Wu Q, Niu M, Yao Q, Li K, Chen Y, Shi C, Chen D, and Feng G, et al. (2010) Anti-inflammatory effect of Sanshuibaihu decoction may be associated with nuclear factor-kappa B and p38 MAPK alpha in collagen-induced arthritis in rat. J Ethnopharmacol 127:264-273.
31. Yang X, Yang J, and Zou H (2013) Baicalin inhibits IL-17-mediated joint inflammation in murine adjuvant-induced arthritis. Clin Dev Immunol 2013:268065.
32. Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA, and Mayo MW (2004) Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23:2369-2380.
33. Yin F, Liu J, Ji X, Wang Y, Zidichouski J, and Zhang J (2011) Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Ab aggregation in SH-SY5Y cells. Neurosci Lett 492:76-79.
34. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, and Antoni C, et al. (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64:1274-1279.